Pfizer Investor Presentation — July 2019

Document content

Earnings Teleconference

July 29, 2019 Introduction

Senior Vice President,

Second Quarter 2019 Earnings Second Quarter 2019 Earnings

3 Forward -Looking Statements and

Non-GAAP Financial Information

 Our discussions during this conference call will include forward- looking statements about, among other things, our anticipated future

operating and financial performance, business plans and prospects, expectations for in- line products and product candidates, including

anticipated regulatory submissions, data read- outs, study starts, approvals, revenue contribution, growth performance, timing of

exclusivity and potential benefits, strategic reviews, capital allocation objectives, business- development plans, the benefits anticipated

from the reorganization of our commercial operations into three businesses which became effective at the beginning of our 2019 f iscal

year, our acquisitions and other business development activities, including our recently -announced proposed transaction with Mylan

N.V. ( Mylan ) to combine Upjohn and Mylan to create a new global pharmaceutical company, our recently announced pending

acquisition of Array BioPharma Inc. and our proposed transaction with GSK to combine our respective consumer healthcare businesses

into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities and prospects, m anufacturing

and product supply and plans relating to share repurchases and dividends that are subject to substantial risks and uncertaint ies that

could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding

these factors can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year ended December 31, 2018 and in our subsequent